Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Claire L SimonsDaniel C MaloneMichael L WangGregory A MaglinteTimothy J InocencioSally W WadeCraig BennisonBijal D ShahPublished in: Journal of medical economics (2021)
The treatment of R/R MCL with KTE-X19 presents a potentially cost-effective alternative to the current SoC, deriving its value from incremental survival and health-related quality-of-life benefits.